达菲Null的患病率及其对基尿素剂量的影响在患有状细胞疾病的儿童中
Jill S Menell1, S Raelle Jackson2, Alissa R Kahn1
1St. Joseph's Children's Hospital, Paterson, New Jersey, USA.
Pediatric blood & cancer
|March 28, 2025
概括
在非洲血统的人群中常见的Duffy零表型与较低的白细胞数量有关. 这项研究发现,患有状细胞病的Duffy null患者需要更低的氧尿素剂量.
科学领域:
- 血液学 血液学 血液学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 达菲无现象型在非洲血统的个体中普遍存在.
- 这种表型与基线白细胞 (WBC) 和中性粒细胞数量减少有关.
- 状细胞病 (SCD) 患者经常接受氧尿素 (HU) 治疗.
研究的目的:
- 调查在接受氨酸尿素治疗的状细胞病患者中Duffy零表型和中性质衰竭之间的关联.
- 确定Duffy零表型是否会影响SCD患者的氧尿素最大耐受剂量 (MTD).
主要方法:
- 对接受基尿素治疗的状细胞病患者的回顾性分析.
- 在Duffy零和Duffy阳性个体之间比较氧尿素最大耐受剂量 (MTD).
- 统计分析以评估观察到的差异的意义.
主要成果:
- 在Duffy零表型患者和Duffy阳性个体 (p = 0.006) 之间观察到HU MTD的统计学上显著差异.
- 患有Duffy零表型患者通常耐受较低剂量的氧尿素.
结论:
- 达菲零表型与状细胞病患者的最大耐受剂量较低的基尿素有关.
- 建议对患有Duffy零表型的个体仔细增加基尿素的剂量.
- 进一步的研究可能会探索这种药物遗传相互作用背后的机制.
相关概念视频
Renal Failure: Dose Adjustments
675
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
675
Drug Dosing: Infants and Children
1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
982
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
982
Pharmacokinetics in Pediatric Patients: Drug Distribution
562
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
562
Pharmacokinetics in Pediatric Patients: Drug Excretion
414
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
414
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
374
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
374


